The p53-stabilizing compound, CP-31398, does not enhance chemosensitivity in human melanoma cells

Related Experiment Video

Updated: Sep 26, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Yvonne Luu1, Gang Li

  • 1Department of Medicine, Division of Dermatology, Vancouver Hospital, Health Sciences Centre, University of British Columbia, Vancouver, BC, Canada.

Anticancer Research
|April 12, 2003
PubMed
Abstract

Insights

The drug CP-31398, which stabilizes p53, did not improve the effectiveness of common chemotherapy drugs in human melanoma cells. This study found no enhanced cell death or apoptosis when CP-31398 was combined with these treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Malignant melanoma presents a significant health challenge due to its metastatic potential and resistance to conventional therapies.
  • The compound CP-31398 shows promise in stabilizing wild-type p53 and enhancing mutant p53 activity, potentially suppressing tumor growth.
  • Given that many chemotherapeutics rely on p53-induced apoptosis, exploring CP-31398's role in sensitizing melanoma cells is warranted.

Purpose of the Study:

  • To determine if the pharmacological compound CP-31398 enhances the chemosensitivity of human melanoma cells.
  • To investigate the effect of CP-31398 on p53 protein levels and its influence on apoptosis induction by standard chemotherapeutic agents.

Main Methods:

  • Human melanoma cell lines with wild-type or mutant p53 were treated with CP-31398 and various anticancer drugs.
  • Cell survival and apoptosis rates were quantified using sulforhodamine B and propidium iodide staining with flow cytometry.
  • Western blotting was employed to assess p53 protein levels.

Main Results:

  • CP-31398 at non-toxic doses increased p53 protein levels in both wild-type and mutant p53 melanoma cell lines.
  • Pretreatment with CP-31398 did not enhance cell death or apoptosis induced by camptothecin, cisplatin, or vincristine.
  • CP-31398 did not augment p53 protein induction when combined with camptothecin.

Conclusions:

  • The compound CP-31398 does not enhance the chemosensitivity of human melanoma cells.
  • Stabilizing p53 with CP-31398 does not improve the efficacy of tested chemotherapeutic drugs against melanoma cells.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...